The SpringWorks Therapeutics, a spinoff of Pfizer, received priority review by the US Food and Drug Admnistration (FDA) for nirogacestat as a treatment for desmoid tumors. Patients taking the small molecule drug as a monotherapy had 71% lower risk of progression and had a better objective response […]
FDA Grants Breakthrough Status for Moderna and Merck’s Vaccine Combo Therapy for Skin Cancer
Moderna and Merck have secured a win with the US Food and Drug Administration (FDA) granting breakthrough therapy designation to the companies’ experimental therapy for skin cancer. The treatment combines a new mRNA vaccine with Merck’s existing drug Keytruda to help the immune system fight […]
BSQ’s Abecma CAR-T Multiple Myeloma Therapy Cuts Progression or Death in Half
Bristol Myers Squibb has released positive new data from its KarMMa-3 trial for Abecma, its CAR-T therapy for multiple myeloma. The results show that patients taking Abecma instead of the current standard of care have 51% reduced risk of death or disease progression. Data also indicates that […]
Kite’s Rare Blood Cancer CAR T-Cell Therapy Improves Survival in Three-Year Followup Data
Kite has announced that its CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), a rare blood cancer with low survival rates, helped improve overall survival in 3-year follow-up data. Patients given the treatment had a median survival of 26 months, with 47% of […]
Siemens Gets FDA and EU Approval for High-Performance Tumor Imaging System
The EU and the US Food and Drug Administration have given approval for Seimens’ Hypersight computed tomography (CT) imaging system. The device, meant to be paired with Seimens Varian radiotherapy systems, produces large, high-contrast images of tumors and surrounding organs in seconds. According […]
FDA Approves Two New Treatments for Breast Cancer and Lymphoma
Eli Lilly and the Menarini Group have both gotten the nod from the US Food and Drug Administration (FDA) for their new cancer medications. Lilly’s therapeutic for relapsed or refractory mantle cell lymphoma, called Jaypirca, is only the fourth drug of its kind approved by the agency. It will cost […]
Bristol Myers Reveals Positive Phase II Data for Leukemia CAR-T Cell Therapy Breyanzi
Bristol Myers Squibb has announced new clinical trial data for its leukemia CAR-T cell therapy Breyanzi. The data shows that the therapy has met its primary endpoint in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), beating standard care in complete […]
J&J and Legend’s CAR-T Therapy Better Than Standard Care in Phase III Trial
J&J and Legend Biotech have announced new results from their CARTITUDE-4 trial that shows their new CAR-T therapy Carvykti is more effective at treating multiple myeloma than standard care. The companies say that the therapy, which many predict to be an upcoming blockbuster, has achieved the […]
Oncology Telehealth Cuts Costs for Some Patients
A newly published paper in JAMA Network Open shows that some cancer patients saved significantly on travel costs by using telehealth oncology services. The study looked at completed telehealth visits from 11,688 adult patients up to 65 years of age and analyzed travel costs and loss of productivity […]
Real-World Data Study Shows Letrozole and Palbociclib Combo Effective for Black or Hispanic Breast Cancer Patients
Although frontline letrozole and palbociclib combination therapy did not improve survival for patients with estrogen receptor-positive, HER2-negative, advanced breast cancer in clinical trials, Black and/or Hispanic patients saw an increase in progression-free survival and overall survival. Dr. Adam […]
